200420-11-7

Upstream product

• 105198-42-3 ethyl (2E)-4-cyclohexyl-2-butenoate 
• 127-65-1 chloroamine-T 
• 162601-64-1 (2R,3S)-2-hydroxy-3-(tosylamino)butano-4-lactone 
• 652976-66-4 N-((R)-2,5-Dioxo-tetrahydro-furan-3-yl)-4-methyl-benzenesulfonamide 
• 162518-06-1 (R)-4-methyl-N-(5-oxotetrahydrofuran-3-yl)benzenesulfonamide 
• 162518-07-2 ethyl (2R,3R)-3-<(N-tosyl)amino>-2-hydroxy-4-iodobutyrate 

Downstream Products

• 203176-14-1 ethyl (2R,3S)-2,3-(N,O-isopropylidene)-3-amino-4-cyclohexyl-2-hydroxybutyrate 
• 185015-78-5 (2R,3S)-4-Cyclohexyl-2-hydroxy-3-(toluene-4-sulfonylamino)-butyric acid 

Relevant academic research and scientific papers

Practical synthesis of Abbott amino-diol: A core unit of the potent renin inhibitor Zankiren

Abbott amino-diol (2S,3R,4S)-2-amino-1-cyclohexyl-6-methyl heptane-3,4- diol 1, a main structural constituent of the orally active renin inhibitor Zankiren has been synthesized using Sharpless asymmetric aminohydroxylation as the key step.

Neighbouring group assisted sulfonamide cleavage of sharpless aminols under acetonation conditions

It is accidentally observed that N-Ts cleavage and simultaneous protection of resulting free amino group as acetonide with the adjacent hydroxy group is achieved in one pot. Neighbouring carboxylic ester group is essential for this transformation.

A short and efficient enantioselective synthesis of cyclohexylnorstatine, a key component of a renin inhibitor

A catalytic asymmetric synthesis of ethyl (2R,35)-N-(p- toluenesulfonyl)-3-amino-4-cyclohexyl-2-hydroxybutyrate 7 in 96% ee from cheaply available cyclohexanone is described employing Sharpless asymmetric aminohydroxylation as the key step.

A concise diastereospecific synthesis of 3-amino-2-hydroxy acids

L-Aspartic acid by N-tosylation, anhydride formation, reduction, α-hydroxylation, iodo esterification and alkylation followed by saponification and deprotection afforded a series of 4-alkyl-3-amino-2-hydroxybutyric acids having the 2S,3R configuration (de